Decoding DPYD: How Genetic Testing Can Reduce Colorectal Cancer Treatment Costs
"A groundbreaking study reveals the impact of DPYD gene variants on fluoropyrimidine toxicity and explores the potential of genetic testing to improve treatment outcomes and manage healthcare expenses."
Colorectal cancer (CRC) treatment often involves fluoropyrimidines, powerful drugs with a significant drawback: unpredictable and sometimes severe toxicity. This toxicity not only diminishes a patient's quality of life and the therapy's effectiveness but also substantially increases healthcare costs. Recognizing the genetic factors influencing drug response is crucial for optimizing treatment strategies and resource allocation.
A critical enzyme in the fluoropyrimidine metabolic pathway is dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene. Genetic variations in DPYD can lead to reduced or absent DPD activity, putting carriers at high risk for life-threatening toxicities. Updated guidelines emphasize the importance of identifying these DPYD variants before starting fluoropyrimidine treatment.
While genetic testing for DPYD variants is available, its adoption in routine clinical practice has been slow. A major hurdle is the lack of comprehensive data demonstrating the cost-effectiveness of preemptive DPYD screening. Addressing this gap, a recent study investigated the association between DPYD variants and the costs associated with managing fluoropyrimidine-related toxicities, offering new insights into personalized cancer care.
Cost and Clinical Impact
DPYD genotyping has been reported as a cost-effective strategy for preventing infrequent but severe, and sometimes fatal, fluoropyrimidine toxicities in patients receiving adjuvant chemotherapy for stage 3 colon cancer. A model-based analysis also found that upfront screening to guide fluoropyrimidine therapy in advanced or metastatic colorectal cancer was cost-saving in Iran. Irish research examined the costs of toxicity-related index hospital admissions after severe reactions in patients tested for four DPYD polymorphisms.
Current Practice and Gaps
Clinical practice may vary in whether DPYD testing is performed before fluoropyrimidine treatment or after toxicity appears. This variation can limit the ability to identify higher-risk patients before exposure. The evidence base and implementation patterns should therefore be interpreted cautiously across healthcare settings.
From Guidance to Implementation
The NCCN colon cancer guideline states that DPYD variant carriers face a significant risk of life-threatening toxicity and identifies DPYD testing as a cost-effective way to reduce that risk. Despite NCCN guidance to consider upfront testing, adoption in the United States has remained limited. A 2026 real-world analysis at two Moffitt Ambulatory Centers studied 233 patients who began fluoropyrimidine therapy between January 2024 and September 2025, reporting estimated toxicity-hospitalization costs of $303,528 versus $44,880 for upfront testing.
Unlocking the Link: DPYD Variants and Treatment Costs
The study, led by researchers at the CRO Aviano National Cancer Institute in Italy and the University of North Carolina, examined data from 550 colorectal cancer patients treated with fluoropyrimidine-based chemotherapy. The researchers retrospectively analyzed the patients' DPYD genotypes for several key variants (DPYD2A, DPYD13, DPYDc.2846A>T, and DPYD-HapB3) and tracked the costs associated with managing any toxicities that arose during treatment.
- Higher Costs: DPYD variant carriers incurred almost four times higher toxicity management costs.
- Increased Hospitalization Risk: These patients had a significantly elevated risk of hospitalization.
- Significant Economic Burden: Just 6.7% of patients (DPYD carriers) accounted for 20.7% of overall treatment costs.
Emerging Evidence
Recent work increasingly evaluates DPYD testing not only as a safety intervention but also as a potential cost-saving strategy. Model-based analyses have examined testing before fluoropyrimidine therapy in both stage 3 colon cancer and advanced or metastatic colorectal cancer. These findings are promising, but their applicability may depend on the healthcare system, treatment setting, and local costs.
Implementation Challenges
The available evidence does not establish that DPYD testing has been implemented consistently in routine practice. Limited adoption may reflect uncertainty about cost-effectiveness, operational barriers, or differences between modeled and real-world care. Results should therefore be considered alongside the possibility that testing programs may not perform identically across institutions.
Prospective Versus Reactive Testing
Comparative analyses have examined prospective DPYD genotyping before adjuvant chemotherapy against no screening for patients with stage 3 colon cancer receiving fluoropyrimidine-based treatment. Separate Irish research compared the anticipated costs of prospective testing with reactive testing after severe toxicity, using hospital admissions among patients with colorectal cancer as an important cost component. Together, these studies frame the economic question as a choice between preventing risk before treatment and identifying susceptibility only after harm occurs.
The Future of Personalized Cancer Care
This research provides a compelling case for incorporating preemptive DPYD screening into routine clinical practice for colorectal cancer patients. By identifying individuals at high risk for fluoropyrimidine-related toxicities, clinicians can adjust treatment regimens, reduce hospitalizations, and ultimately lower healthcare costs. As genetic testing becomes more accessible and affordable, personalized medicine approaches like DPYD screening promise to transform cancer care, improving both patient outcomes and resource utilization.
Interpreting the Evidence
The evidence supports viewing DPYD testing as both a patient-safety measure and a possible economic intervention. However, cost-effectiveness findings are shaped by assumptions about toxicity, treatment, testing, and healthcare costs. Expert interpretation should distinguish model projections from outcomes observed in routine practice.
Expanding the Evidence Base
Future research may clarify how upfront DPYD testing performs across cancer stages, healthcare systems, and treatment pathways. Prospective studies could help determine whether modeled savings translate into routine-care results. Broader implementation evidence may also explain why testing remains limited despite supportive guidance.
Systems and Access
The value of DPYD testing depends not only on the test itself but also on whether clinicians can order it, interpret results, and adapt fluoropyrimidine treatment. Differences in hospital costs and healthcare infrastructure may produce different economic conclusions. System-level adoption therefore remains an important consideration when applying evidence across countries and institutions.
Patient Safety in Practice
The central human benefit of DPYD testing is the possibility of reducing exposure to severe fluoropyrimidine toxicity before treatment begins. Preventing serious reactions may also help patients remain on an effective cancer-treatment plan. Because individual outcomes can differ, testing decisions should be integrated with clinical judgment and shared patient care.